The twentieth century has been a great success for modern medicine, and has resulted in the generation of a plethora of drugs to treat most common illnesses. However, in the light of increasing regulatory demands, spiralling costs and diminishing commercial returns, the question of how, when, where and whether to conduct pharmaceutical R&D has profound implications, and not just for those within the pharmaceutical industry. In response to these and other dilemmas, the authors define the processes involved in drug research, and examine the advantages and disadvantages of collaborative methods of drug research, and examine the roles that academia, CROs, small "biotechnology" companies and "research boutiques," and possibly even the "virtual research company" might play as contractors and collaborators.
Modern Strategy for Preclinical Pharmaceutical R&D
and over one million other books are available for Amazon Kindle.
Learn more
FREE Two-Day Shipping for students on millions of items. Learn more |
| |||||||||||||||
Book Description
Special Offers and Product Promotions
- Buy $50 in qualifying physical textbooks, get $5 in Amazon MP3 Credit. Here's how (restrictions apply)
Editorial Reviews
From the Publisher
The twentieth century has been a great success for modern medicine, and has resulted in the generation of a plethora of drugs to treat most common illnesses. However, in the light of increasing regulatory demands, spiralling costs and diminishing commercial returns, the question of how, when, where and whether to conduct pharmaceutical R&D has profound implications, and not just for those within the pharmaceutical industry. In response to these and other dilemmas, the authors define the processes involved in drug research, and examine the advantages and disadvantages of collaborative methods of drug research, and examine the roles that academia, CROs, small "biotechnology" companies and "research boutiques," and possibly even the "virtual research company" might play as contractors and collaborators.
From the Back Cover
Modern Strategy for Preclinical Pharmaceutical R&D Towards the Virtual Research Company David Cavalla Arachnova Ltd, Cambridge, UK With contributions from: John Flack AMRAD Corporation, Richmond, Australia and Richard Jennings Wolfson Industrial Liaison Office, University of Cambridge, UK The twentieth century has been a great success for modern medicine, and has resulted in the generation of a plethora of drugs to treat most common illnesses. However, in the light of increasing regulatory demands, spiralling costs and diminishing commercial returns, the question of how, when, where and whether to conduct pharmaceutical R&D has profound implications, and not just for those within the pharmaceutical industry. Modern Strategy for Preclinical Pharmaceutical R&D gets to the heart of the debate that surrounds this topic and asks the questions: Can the economies of scale of large multinational pharmaceutical companies adequately compensate for the loss of creative individualism that is essential for the process of drug discovery and development? Might technological experts provide better services to a number of clients rather than work within a single large infrastructure where confidentiality is paramount and synergy of multi-disciplinary operation readily possible? What are the long-term prospects for the latest alternatives to large pharmaceutical R&D companies? In response to these and other dilemmas, the authors define the processes involved in drug R&D, explore the advantages and disadvantages of collaborative methods of drug research, and examine the roles that academia, CROs, small 'biotechnology' companies and 'research boutiques', and possibly even the 'virtual research company' might play as contractors and collaborators. Without a doubt, Modern Strategy for Preclinical Pharmaceutical R&D is essential reading for all those interested in making sense of the confusion that surrounds today's pharmaceutical industry.
Product Details
Would you like to update product info or give feedback on images?
|
More About the Author
Discover books, learn about writers, read author blogs, and more.
Customer Reviews
|
Share your thoughts with other customers:
|
||||||||||||||||||||||
|
Most Helpful Customer Reviews
1 of 1 people found the following review helpful:
1.0 out of 5 stars
What you learn from this book is not worth the money,
By
This review is from: Modern Strategy for Preclinical Pharmaceutical R&D: Towards the Virtual Research Company (Hardcover)
This book is way overpriced for the information that it delivers. Besides being out-of-date, it focuses on what might be called discovery outsourcing with minimal information about preclinical development outsourcing. The author has littl to add, though he does explain preclinical research and the factors involved in its success rather lucidly. It's certainly not use the price they want for it. Find it used for less than $50 and it will be a reasonable purchase.
Share your thoughts with other customers: Create your own review
|
|
Inside This Book
(learn more)
First Sentence:
There is an ongoing debate about the correct response to the intensifying pressures, relating to the increasing costs of new products, and the decreasing returns besetting the pharmaceutical industry. Read the first page Key Phrases - Statistically Improbable Phrases (SIPs): (learn more)
virtual research company, contract research organisations, biotechnology sector, drug delivery technology, combinatorial chemistry, milestone payments, preclinical development, large pharmaceutical companies, discovery chemistry, technology providers Key Phrases - Capitalized Phrases (CAPs): (learn more)
Glaxo Wellcome, Oxford Diversity, Oxford Asymmetry, Peptide Therapeutics, Hoechst Marion Roussel, Oxford Molecular, Parke Davis, North Carolina, British Technology Group, Harvard University, Recombinant Capital, The Wellcome Trust, University of Cambridge, World Wide Web, British Biotech New!
Books on Related Topics | Concordance | Text Stats Browse Sample Pages:
Front Cover | Table of Contents | First Pages | Index | Back Cover | Surprise Me!
There is an ongoing debate about the correct response to the intensifying pressures, relating to the increasing costs of new products, and the decreasing returns besetting the pharmaceutical industry. Read the first page Key Phrases - Statistically Improbable Phrases (SIPs): (learn more)
virtual research company, contract research organisations, biotechnology sector, drug delivery technology, combinatorial chemistry, milestone payments, preclinical development, large pharmaceutical companies, discovery chemistry, technology providers Key Phrases - Capitalized Phrases (CAPs): (learn more)
Glaxo Wellcome, Oxford Diversity, Oxford Asymmetry, Peptide Therapeutics, Hoechst Marion Roussel, Oxford Molecular, Parke Davis, North Carolina, British Technology Group, Harvard University, Recombinant Capital, The Wellcome Trust, University of Cambridge, World Wide Web, British Biotech New!
Books on Related Topics | Concordance | Text Stats Browse Sample Pages:
Front Cover | Table of Contents | First Pages | Index | Back Cover | Surprise Me!
Citations (learn more)
This book cites 8
books:
See all 8 books this book cites
- Technology Transfer: Making the Most of Your Intellectual Property by Neil F. Sullivan in Back Matter
- Universities and Industrial Research by Ewald Konecny in Back Matter
- Drug Discovery & Development (Contemporary Biomedicine) by Michael Williams in Back Matter
- Medicinal Chemistry: Principles and Practice by Frank D King in Back Matter
- Multinational Drug Companies: Issues in Drug Discovery and Development by Bert Spilker in Back Matter
See all 8 books this book cites
Books on Related Topics
(learn more)
|
Tags Customers Associate with This Product(What's this?)Click on a tag to find related items, discussions, and people.
|
Customer Discussions
|
This product's forum
Active discussions in related forums
Search Customer Discussions
|
Related forums
|
